248 related articles for article (PubMed ID: 34181866)
1. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
[No Abstract] [Full Text] [Related]
2. Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
Kimmig LM; Liao C; Bag R
Lung; 2020 Feb; 198(1):53-58. PubMed ID: 31912412
[TBL] [Abstract][Full Text] [Related]
3. Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids.
Bartolome SD; Sood N; Shah TG; Styrvoky K; Torres F; Chin KM
Chest; 2018 Sep; 154(3):532-540. PubMed ID: 29679599
[TBL] [Abstract][Full Text] [Related]
4. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension.
Harutyunova S; Benjamin N; Eichstaedt C; Marra AM; Xanthouli P; Nagel C; GrĂ¼nig E; Egenlauf B
Respiration; 2023; 102(8):579-590. PubMed ID: 37544296
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review.
Feenstra J; Hopkins P; Trotter M; O'Brien K
Intern Med J; 2020 Nov; 50(11):1377-1384. PubMed ID: 31661174
[TBL] [Abstract][Full Text] [Related]
8. An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.
Oudiz R; Agarwal M; Rischard F; De Marco T
Pulm Circ; 2016 Dec; 6(4):532-538. PubMed ID: 28090295
[TBL] [Abstract][Full Text] [Related]
9. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
10. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
McLaughlin VV; Palevsky HI
Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
[TBL] [Abstract][Full Text] [Related]
11. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
Sarangarm P; Elwood K
Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
14. Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review.
Park K; Ostrow D; Levy RD; Swiston J
Can Respir J; 2011; 18(3):157-62. PubMed ID: 21766080
[TBL] [Abstract][Full Text] [Related]
15. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
16. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?
Rich J; Hoeper MM
Int J Clin Pract Suppl; 2009 Mar; (161):17-8. PubMed ID: 19178601
[TBL] [Abstract][Full Text] [Related]
17. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.
Oudiz RJ; Farber HW
Am Heart J; 2009 Apr; 157(4):625-35. PubMed ID: 19332188
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term bosentan in children with pulmonary arterial hypertension.
Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ
J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438
[TBL] [Abstract][Full Text] [Related]
19. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Diaz-Guzman E; Heresi GA; Dweik RA; Minai OA
Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130
[TBL] [Abstract][Full Text] [Related]
20. Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N; Lang I
Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1391-9. PubMed ID: 25363827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]